Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial.

The primary endpoint did not reach statistical significance at the α = 0.05 level ( p = 0.054); nevertheless, the observed magnitude of improvement exceeded the established minimal clinically important differences (MCIDs).

also in 111,027 other papers